ACRO BIOMEDICAL CO., LTD.: 10-Q filed 2019-08-14

Name: ACRO BIOMEDICAL CO., LTD.: 10-Q filed 2019-08-14
Creator: ACRO BIOMEDICAL CO., LTD.

What ACRO BIOMEDICAL CO., LTD. reported in its quarterly report filed 2019-08-14 (fiscal Q3 2019): 23 published measures, 66 facts as tagged in accession 0001640334-19-001630.

This filing

Form: 10-Q (quarterly report)
Filed: 2019-08-14
Fiscal period: fiscal Q3 2019
Accession: 0001640334-19-001630 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACRO BIOMEDICAL CO., LTD. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-06-30	1,081,094	USD
At 2018-09-30	1,482,829	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2019-06-30	133,091	USD
At 2018-09-30	240,675	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2019-06-30	948,003	USD
At 2019-03-31	998,218	USD
At 2018-12-31	1,167,860	USD
At 2018-09-30	1,242,154	USD
At 2018-06-30	777,319	USD
At 2018-03-31	661,010	USD
At 2017-12-31	591,558	USD
At 2017-09-30	511,331	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2019-06-30	231	USD
At 2018-09-30	1,148	USD
At 2018-06-30	4,615	USD
At 2017-09-30	36,810	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	-50,824	USD	91
2018-10-01 to 2019-06-30	-295,590	USD	273
2019-01-01 to 2019-03-31	-169,750	USD	90
2018-10-01 to 2018-12-31	-75,016	USD	92
2018-04-01 to 2018-06-30	116,309	USD	91
2017-10-01 to 2018-06-30	265,988	USD	273
2018-01-01 to 2018-03-31	69,452	USD	90
2017-10-01 to 2017-12-31	80,227	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2018-10-01 to 2019-06-30	36,818	USD	273
2017-10-01 to 2018-06-30	-136,252	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2018-10-01 to 2019-06-30	-37,735	USD	273
2017-10-01 to 2018-06-30	104,057	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-06-30	29,829	USD
At 2018-09-30	325,419	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	-17,877	USD	91
2018-10-01 to 2019-06-30	-82,942	USD	273
2018-04-01 to 2018-06-30	59,917	USD	91
2017-10-01 to 2018-06-30	88,476	USD	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2018-10-01 to 2019-06-30	300,089	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-06-30	1,071,223	USD
At 2018-09-30	1,477,837	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2019-06-30	133,091	USD
At 2018-09-30	240,675	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	68,092	USD	91
2018-10-01 to 2019-06-30	512,493	USD	273
2018-04-01 to 2018-06-30	63,674	USD	91
2017-10-01 to 2018-06-30	226,336	USD	273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2019-06-30	1,060,000	USD
At 2018-09-30	1,146,600	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2018-10-01 to 2019-06-30	135,400	USD	273
2018-04-01 to 2018-06-30	239,900	USD	91
2017-10-01 to 2018-06-30	580,800	USD	273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2018-10-01 to 2019-06-30	1,218,600	USD	273
2018-04-01 to 2018-06-30	1,959,100	USD	91
2017-10-01 to 2018-06-30	5,027,200	USD	273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	68,092	USD	91
2018-10-01 to 2019-06-30	512,493	USD	273
2018-04-01 to 2018-06-30	63,674	USD	91
2017-10-01 to 2018-06-30	226,336	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-06-30	47,760,000	shares
At 2018-09-30	47,760,000	shares

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2019-06-30	9,871	USD
At 2018-09-30	0	USD

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	-609	USD	91
2018-10-01 to 2019-06-30	-1,439	USD	273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

Period	Value	Unit	Days
2018-10-01 to 2019-06-30	-9,871	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2018-10-01 to 2019-06-30	0	USD	273
2017-10-01 to 2018-06-30	0	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2018-10-01 to 2019-06-30	-86,600	USD	273
2017-10-01 to 2018-06-30	439,000	USD	273

Inspect the source

Entity: ACRO BIOMEDICAL CO., LTD. / CIK 0001622996
Captured: 2026-09-19T11:19:47.057Z
SEC response SHA-256: b3abbbd950a9b9c0ba03d5604cc52c43ddb41d59ea263147bca632d90b36b6c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001622996.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))